Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Recursion Pharmaceuticals (RXRX) closed at $8.19 in the latest trading session, marking a -1.92% move from the prior day.

Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

The consensus price target hints at a 43.7% upside potential for Recursion Pharmaceuticals (RXRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know

Recursion Pharmaceuticals is looking to revolutionize the drug development process. The biotech's strategy has yet to deliver major medical breakthroughs.

1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell

Medtronic

Novartis

While the pairing of artificial intelligence and healthcare may sound like something straight out of a science fiction movie, there are several avenues through which the high-speed data processing offered by AI can improve patient outcomes. From more precise diagnosis to pandemic modeling, the large-scale algorithmic models we call AI can help the world of medicine immensely.

3 Healthcare Stocks Injecting AI for Big Gains

Nano-X Imaging

NVIDIA

SoundHound AI Inc

Nano-X Imaging is especially popular with analysts. Recursion Pharmaceuticals plans to report results from seven clinical studies over the next 18 months.

These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street

Denali Therapeutics

Geron

The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.

3 Longevity Stocks to Buy for Anti-Aging Breakthroughs

Beam Therapeutics

Lilium BV

Amazon (NASDAQ: AMZN ) has more skin in the AI game than many people would like to think. Of course, the first thing that would spring to mind is the company's AWS cloud division.

3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030

Moderna

Intellia Therapeutics

Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical trials.

Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet

SoFi Technologies

Stem, Inc

Last week, Nvidia (NASDAQ: NVDA ) briefly eclipsed Microsoft (NASDAQ: MSFT ) as the world's most valuable company. The AI chip maker is now worth $3.

3 AI Stocks on the Edge of a Massive Surge

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.50 per share. All of the shares are to be sold by Recursion. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an additional 4,615,384 shares of its Class A common stock.  Before deducting the underwriting discounts and commissions and estimated offering expenses, Recursion expects to receive total gross proceeds of approximately $200 million, assuming no exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about June 28, 2024, subject to satisfaction of customary closing conditions.

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering. All of the shares of Class A common stock are being offered by Recursion. In addition, Recursion intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock offered. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Recursion Announces Proposed Offering of Class A Common Stock

Recursion Pharmaceuticals (RXRX) reachead $9.38 at the closing of the latest trading day, reflecting a +0.43% change compared to its last close.

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

SAN MATEO, Calif.--(BUSINESS WIRE)--Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with Recursion Pharmaceuticals (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to industrialize drug discovery. Recursion will have access to de-identified clinico-genomic data, collected from research participants who consent to participate in Helix's extensive research network, wh.

Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data

SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to investors, analysts, and other stakeholders during Download Day, Recursion's investor and R&D day, on Monday, June 24, 2024.

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

This thesis makes the case for an investment in Recursion Pharmaceuticals operating as a TechBio which "industrializes" the process of drug discovery in contrast to a typical biotech. The difference between TechBio and biotech may appear subtle, but is an important one that may have motivated Nvidia to invest $50 million. Based on the value of its platform and data assets, it is a buy with a 48.5% upside potential.

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and strategic partnerships with biopharmaceutical companies. While Recursion is probably the best positioned AI drug discovery company, the stock could pull back if AI hype fades.

Recursion Pharmaceuticals: Unprecedented Scale

Altimmune

EVgo

Low-priced stocks under $10 can be explosively awarding. That is, if you spot the right one at the right time with the right catalyst.

3 Stocks Under $10 Set to Quadruple by 2025: June Edition

ARM Holdings PLC

Nvidia has been one of the best-performing stocks on Wall Street since 2023, amassing holdings in four companies along the way.

Nvidia Owns These 4 Stocks. Here's How They're Doing.

Recursion hopes to transform the healthcare industry with its innovative drug discovery platform. The small company has gained the interest of Nvidia, which has invested in the business.

Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim

Fabrinet

The AI craze may be slowing, but that doesn't mean there's not plenty of opportunity available. While investing heavily in Nvidia (NASDAQ: NVDA ) could keep the cash coming in (considering its recent performance), there's a more cost-effective strategy to leverage Nvidia's growth: investing in Nvidia partner stocks, which stand to benefit from Nvidia's expansive influence across various industries.

Nvidia's Golden Handshake: 3 Stocks Reaping the Rewards of an NVDA Alliance

Viking Therapeutics

Biotechs that aspire to be disruptive are quite risky. However, they do offer the chance of disproportionate rewards.

1 Disruptive Biotech Stock to Buy Now, and 1 to Consider

Cathie Wood Owns These 2 AI Stocks. Should You?

Recursion Pharmaceuticals hopes to use AI to accelerate drug discovery in the healthcare industry. its ambitious plans are still unproven, and the business has no approved products of its own.

Is Recursion Pharmaceuticals Stock a Millionaire-Maker?

Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in CRISPR-Cas9 gene knockouts and a debiasing (correcting) algorithm. Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in CRISPR-Cas9 gene knockouts and a debiasing (correcting) algorithm.

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

News for Recursion Pharmaceuticals Stock (RXRX)